Published in Hepatitis Weekly, August 1st, 2005
"Chronic hepatitis B (CHB) is an important cause of end stage liver disease and hepatocellular carcinoma. Controlled clinical trials indicate treatment with lamivudine results in positive clinical responses," scientists in the United States report.
"The study goal was to determine if the response to lamivudine treatment (hepatitis e antigen [HBeAg] loss, hepatitis B virus [HBV] DNA loss and alanine aminotransferase [ALT] reduction) differs according to pretherapy (pre-tx) ALT levels. This was a retrospective review of medical record data," said H.W. Hann and colleagues,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.